Current Pharmaceutical Design

Author(s): Laura de Ramon, Marta Jarque, Elia Ripoll, Oriol Bestard, Josep M. Grinyo and Juan Torras

DOI: 10.2174/1381612822666160719103955

DownloadDownload PDF Flyer Cite As
RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets

Page: [4651 - 4657] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Ischemia reperfusion injury is an important pathophysiological process in many fields such as transplantation, stroke, atherosclerosis, trauma and myocardial infarction. Recent advances in gene silencing may help to reduce ischemic effects, targeting molecules related to this pathological process. Methods and results: Here, we review the different silencing approaches in ischemic injury, highlighting the role of co-stimulatory molecules in renal transplantation. Conclusion: Gene silencing appears as a new strategy to prevent the inflammation and injury associated with ischemia.

Keywords: Ischemia, siRNA, gene silencing, CD40.